GM102, a first-in-class monoclonal glyco-engineered antibody (Ab) targeting Anti-Mullerian – Hormone-Receptor II (AMHRII): safety and hints of activity in Granulosa Cell Tumors (GCT)

ENA 2018 Poster #LBA15